Released on = August 1, 2007, 5:20 am

Press Release Author = Lala C. Ballatan

Industry = Law

Press Release Summary = A new study on Centers for Disease Control and Prevention
(CDC) was released by the New England Journal of Medicine or NEJM showing results in
the use of some antidepressants in the course of pregnancy. According to the study,
the use of these antidepressants during certain stages in pregnancy, like in
particular, the \"selective serotonin-reuptake inhibitors or widely known as the
SSRIs, have not significant effect on the increase in risk of having birth defects.

Press Release Body = A new study on Centers for Disease Control and Prevention (CDC)
was released by the New England Journal of Medicine or NEJM showing results in the
use of some antidepressants in the course of pregnancy. According to the study, the
use of these antidepressants during certain stages in pregnancy, like in particular,
the \"selective serotonin-reuptake inhibitors or widely known as the SSRIs, have not
significant effect on the increase in risk of having birth defects.

Los Angeles, California, July 27 - 2007 - The study was entitled \"Use of Selective
Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects.\" It has
discovered that there are few or no significant increase involved in the threats of
acquiring most birth defects during the time all of the SSRIs have been studied
simultaneously.

The findings of the study includes birth defect risks like congenital heart disease,
which was once associated with the use of SSRI in earlier studies. However,
researchers have also found out that there were associations between the use of SSRI
and three definite defects in birth. These defects involve the brain, one kind of
abnormality in development of the skull and in the gastrointestinal organ.

According to CDC\'s epidemiologist, Jennita Reefhuis, the overall results of their
studies were generally encouraging, especially regarding the issue of
antidepressants use for the duration of pregnancy. Reefhuis is also among the group
of authors that spearheaded the study.

Reefhuis further stipulated that it is known that the mother and infant both benefit
once the pregnant women who has critical depressive illness manages to stay with
certain treatment. The threats have differences according to various SSRIs and
categorization of women.

Reefhuis stated that it is important for the pregnant women to discuss the benefits
and risks of SSRI medication during the time of their pregnancy. She also noted that
even if their study have found some association between the increased threat of
having three explicit birth defects associated with SSRI use, the increase are
actually minimal and were not discovered previously on studies concerning same
issue.

A second SSRI study in connection with birth defects that was published by NEJM on
June 28 that has not found any such association with overall birth defects. On the
other hand, it found important connections between certain SSRIs and a number of
birth defects.

Reefhuis declared that for every pregnancy there is a 3 percent risk of having
defects during birth, without regard to exposures to antidepressants. There is a
lifetime risk for women to acquire major depression by 10 - 25 percent. The highest
prevalence of this is when they are in their childbearing years of during 18 - 44
years old.
The CDC has intentions of continuing their study the associations of SSRI and risks
of birth defects in order to shed light on whether there is a true risk existing
with the antidepressant use while pregnant.

Los Angeles Personal Injury Lawyers, Attorneys and Law Firms - We provide quality
legal service for our clients in order for you to obtain only the best possible
settlement for your personal injury claims. Likewise, our Personal Injury Lawyers
assure you, our clients that your personal injury cases will always be given utmost
priority and will be handled with great competence and dedication. Log on to our
website
Web Site = http://www.personalinjurylawyerinc.com

Contact Details = carlab@mesriani.com